Citadel Advisors
VRDN icon

Citadel Advisors’s Viridian Therapeutics VRDN Stock Holding History

Citadel Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.56M Buy
+139,100
New +$2.24M ﹤0.01% 6018
2026
Q1 		– Sell
-14,600
Closed -$454K – 14337
2025
Q4 		$454K Sell
14,600
-1,000
-6% -$27.4K ﹤0.01% 9258
2025
Q3 		$337K Sell
15,600
-11,100
-42% -$200K ﹤0.01% 10102
2025
Q2 		$373K Sell
26,700
-8,900
-25% -$121K ﹤0.01% 9310
2025
Q1 		$480K Sell
35,600
-7,600
-18% -$129K ﹤0.01% 8561
2024
Q4 		$828K Buy
43,200
+15,000
+53% +$326K ﹤0.01% 7443
2024
Q3 		$642K Sell
28,200
-3,100
-10% -$50.7K ﹤0.01% 7732
2024
Q2 		$407K Buy
31,300
+1,200
+4% +$16.6K ﹤0.01% 8477
2024
Q1 		$527K Buy
30,100
+9,500
+46% +$184K ﹤0.01% 8280
2023
Q4 		$449K Buy
20,600
+17,000
+472% +$268K ﹤0.01% 8341
2023
Q3 		$55.2K Sell
3,600
-11,800
-77% -$225K ﹤0.01% 11642
2023
Q2 		$366K Buy
15,400
+1,900
+14% +$48.7K ﹤0.01% 8602
2023
Q1 		$343K Sell
13,500
-7,000
-34% -$224K ﹤0.01% 9095
2022
Q4 		$599K Sell
20,500
-53,100
-72% -$1.22M ﹤0.01% 7865
2022
Q3 		$1.51M Sell
73,600
-19,100
-21% -$343K ﹤0.01% 6140
2022
Q2 		$1.07M Buy
+92,700
New +$1.25M ﹤0.01% 6857

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Citadel Advisors's VRDN Position: Q2 2026 in Review

Citadel Advisors reduced its Viridian Therapeutics (VRDN) stake by 98% in Q2 2026, selling an estimated $36.7M and leaving 41,303 shares worth $759K. The position accounts for ﹤0.01% of the portfolio, ranked #8878.

Citadel Advisors first reported a position in VRDN in Q4 2015 and has held it in 32 quarters since. The position peaked at $45.3M in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Citadel Advisors held 41,303 shares of Viridian Therapeutics worth $759K as of Q2 2026.
  • Citadel Advisors sold 2,276,931 Viridian Therapeutics shares in Q2 2026, an estimated $36.7M.
  • Viridian Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8878 holding.
  • Citadel Advisors first reported a position in Viridian Therapeutics in Q4 2015 and has held it in 32 quarters since.
  • Citadel Advisors's Viridian Therapeutics position peaked at $45.3M in Q1 2026.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.